Business Description
Lytix Biopharma AS
ISIN : NO0010405780
Share Class Description:
STU:6BG: Ordinary SharesDescription
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401, and LTX-315 are in the pipeline.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.44 | |||||
| Equity-to-Asset | 0.65 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 8.94 | |||||
| Beneish M-Score | 0.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -25.9 | |||||
| 3-Year EPS without NRI Growth Rate | -26.3 | |||||
| 3-Year FCF Growth Rate | -56.1 | |||||
| 3-Year Book Growth Rate | 35.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.01 | |||||
| 9-Day RSI | 30.26 | |||||
| 14-Day RSI | 37.55 | |||||
| 6-1 Month Momentum % | -33.2 | |||||
| 12-1 Month Momentum % | 10.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.07 | |||||
| Quick Ratio | 3.07 | |||||
| Cash Ratio | 2.5 | |||||
| Days Sales Outstanding | 376.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | -12.36 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -770.24 | |||||
| Net Margin % | -752.27 | |||||
| FCF Margin % | -759.59 | |||||
| ROE % | -161.78 | |||||
| ROA % | -125.15 | |||||
| ROIC % | -652.01 | |||||
| ROC (Joel Greenblatt) % | -2554.13 | |||||
| ROCE % | -144.99 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 27.72 | |||||
| PB Ratio | 8.03 | |||||
| Price-to-Tangible-Book | 7.7 | |||||
| EV-to-EBIT | -4.96 | |||||
| EV-to-EBITDA | -5.02 | |||||
| EV-to-Revenue | 34.04 | |||||
| EV-to-FCF | -4.47 | |||||
| Price-to-Net-Current-Asset-Value | 9.24 | |||||
| Price-to-Net-Cash | 11.55 | |||||
| Earnings Yield (Greenblatt) % | -20.16 | |||||
| FCF Yield % | -20.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lytix Biopharma AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.933 | ||
| EPS (TTM) (€) | -0.16 | ||
| Beta | -0.35 | ||
| Volatility % | 95.67 | ||
| 14-Day RSI | 37.55 | ||
| 14-Day ATR (€) | 0.049704 | ||
| 20-Day SMA (€) | 0.5727 | ||
| 12-1 Month Momentum % | 10.23 | ||
| 52-Week Range (€) | 0.332 - 1.075 | ||
| Shares Outstanding (Mil) | 68.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lytix Biopharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lytix Biopharma AS Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lytix Biopharma AS Frequently Asked Questions
What is Lytix Biopharma AS(STU:6BG)'s stock price today?
The current price of STU:6BG is €0.46. The 52 week high of STU:6BG is €1.08 and 52 week low is €0.33.
When is next earnings date of Lytix Biopharma AS(STU:6BG)?
The next earnings date of Lytix Biopharma AS(STU:6BG) is 2025-02-28 Est..
Does Lytix Biopharma AS(STU:6BG) pay dividends? If so, how much?
Lytix Biopharma AS(STU:6BG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers